News and Events

Phase 1 clinical trial of rhIL-15 plus standard treatment for children and young adults with relapsed/refractory neuroblastoma

A clinical trial led by Rosa Nguyen, M.D., Ph.D., in the Pediatric Oncology Branch is researching whether adding an immunotherapy, rhIL-15, to three standard treatments will improve treatment results for neuroblastoma that has come back or not responded to treatment in children and young adults.

Phase 2 Trial Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

A clinical trial led by Christopher J. Melani, M.D., Associate Research Physician in the Lymphoid Malignancies Branch is testing the effectiveness of a combination targeted therapy known as ViPOR for patients with relapsed and/or refractory aggressive B-cell lymphoma.

Immunofluorescence image of the cell adhesion protein basigin (turquoise) in TuNEPs released from dying 4T1 mouse breast cancer cells.

Proteins Released from the Nuclei of Dying Cancer Cells Promote Tumor Growth

Material released from dying cancer cells, known as tumor cell nuclear expulsion products (TuNEPs), contains specific proteins that promote the growth of neighboring cancer cells. Targeting these proteins could lead to new treatments that hinder cancer spread and improve patient outcomes.

An illustration of papillomas in the throat

CCR Research Leads to FDA Approval of First Immunotherapy for Recurrent Respiratory Papillomatosis

The U.S. Food and Drug Administration has granted full market approval for Papzimeos (zopapogene imadenovec-drba), a groundbreaking non-replicating adenoviral vector-based immunotherapy designed for adult patients with recurrent respiratory papillomatosis (RRP).

a small cluster of cancer cells that has spread from the primary tumor

Protein makes cancer cells easier to destroy with immunotherapy

A protein called GCN1 can trigger a stress response inside cancer cells and simultaneously help them hide from the immune system. Research found these processes can be blocked by another protein called IMPACT, which could enhance immunotherapy’s ability to find and kill cancer cells.

Clinical trial researching immunotherapy for head and neck cancer

A clinical trial led by Charalampos Floudas, M.D., D.M.Sc., M.S., Associate Research Physician in the Center for Immuno-Oncology, is researching a combination immunotherapy for adults with head and neck squamous cell carcinoma.

Headshots of Dr. Jiang, Dr. Shah, and Dr. Zhang

Three CCR researchers appointed as Senior Investigators

The CCR community congratulates Peng Jiang, Ph.D., Nirali N. Shah, M.D., M.H.Sc., and Ping Zhang, Ph.D., for recently being appointed as Senior Investigators in their respective labs and branches.

Clinical trial researching CAR T-cell therapy for rhabdomyosarcoma

A clinical trial led by Srivandana Akshintala, M.B.B.S., M.P.H., Assistant Research Physician in the Pediatric Oncology Branch, is researching CAR T-cell therapy for children and young adults with rhabdomyosarcoma.

Celebrating CCR Careers: Stefan Ambs, Ph.D., M.P.H.

Stefan Ambs, Ph.D., M.P.H., is a molecular epidemiologist whose expertise is in prostate and breast cancer with a focus on cancer health disparities and risk factors that alter the tumor microenvironment. After almost 25 years at the NCI, he retired in May 2025.

Clinical trial researching drug therapy for solid tumors

A clinical trial led by Hoyoung M. Maeng, M.D., Associate Research Physician in the Center for Immuno-Oncology, is researching a drug therapy for adults with advanced solid tumors.

Breadcrumb